

First Wave BioPharma Inc (FWBI) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/ACF0E1D9746EN.html>

Date: November 2021

Pages: 44

Price: US\$ 125.00 (Single User License)

ID: ACF0E1D9746EN

Abstracts

First Wave BioPharma Inc (FWBI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

First Wave BioPharma Inc (First Wave BioPharma), formerly AzurRx BioPharma Inc, is a development stage biopharmaceutical company which focuses on non-systemic biologics for the treatment of patients with gastrointestinal disorders. The company's products under development include MS1819 a non-systemic yeast recombinant enzyme intended for the treatment of exocrine pancreatic insufficiency exocrine (EPI) in patients with cystic fibrosis (CF) and chronic pancreatitis (CP). MS1819 completed phase IIa trial in partnership with Mayoly which is a European Pharmaceutical company. Its pre-clinical products include AZX1103 and AZX1101 which is recombinant beta lactamases enzyme for the prevention of nosocomial (hospital-acquired) infections and antibiotic-associated diarrhea. The company has operations in France and the US. First Wave BioPharma is headquartered in Brooklyn, New York, the US.

First Wave BioPharma Inc Key Recent Developments

Oct 12,2021: First Wave BioPharma Announces Two Additions to Scientific Advisory Board

Sep 14,2021: AzurRx BioPharma to acquire First Wave Bio for \$229m

Sep 13,2021: AzurRx BioPharma announces acquisition of first wave bio and its

proprietary Niclosamide Formulations targeting multi-billion dollar Inflammatory Bowel Disease Indications

Sep 07,2021: AzurRx BioPharma to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference

Aug 16,2021: AzurRx BioPharma Announces Appointment of Terry Coelho to its Board of Directors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the

revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

First Wave BioPharma Inc - Key Facts
First Wave BioPharma Inc - Key Employees
First Wave BioPharma Inc - Key Employee Biographies
First Wave BioPharma Inc - Major Products and Services
First Wave BioPharma Inc - History
First Wave BioPharma Inc - Company Statement
First Wave BioPharma Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
First Wave BioPharma Inc - Business Description
First Wave BioPharma Inc - SWOT Analysis
SWOT Analysis - Overview
First Wave BioPharma Inc - Strengths
First Wave BioPharma Inc - Weaknesses
First Wave BioPharma Inc - Opportunities
First Wave BioPharma Inc - Threats
First Wave BioPharma Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

First Wave BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD
2021

First Wave BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021

First Wave BioPharma Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Oct 12, 2021: First Wave BioPharma Announces Two Additions to Scientific Advisory Board

Sep 07, 2021: AzurRx BioPharma to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference

Aug 16, 2021: AzurRx BioPharma Announces Appointment of Terry Coelho to its Board of Directors

Jun 08, 2021: RedHill concludes enrolment in Phase II/III Covid-19 drug trial

Jun 08, 2021: AzurRx BioPharma CEO James Sapirstein to present at 2021 BIO Digital

May 19, 2021: AzurRx BioPharma to Present at Rocky Mountain Microcap Conference (May 26)

May 11, 2021: AzurRx BioPharma to Present at Investor Summit Group’s Q2 Virtual Investor Summit (May 17)

May 11, 2021: AzurRx BioPharma to Present at the Emerging Growth Conference

Mar 31, 2021: AzurRx BioPharma Provides Key Takeaways from Phase 2b OPTION 2 Clinical Trial Topline Results Conference Call

Mar 08, 2021: AzurRx BioPharma to Participate in the 33rd Annual Roth Conference

SECTION 6 – APPENDIX

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

First Wave BioPharma Inc, Key Facts
First Wave BioPharma Inc, Key Employees
First Wave BioPharma Inc, Key Employee Biographies
First Wave BioPharma Inc, Major Products and Services
First Wave BioPharma Inc, History
First Wave BioPharma Inc, Subsidiaries
First Wave BioPharma Inc, Key Competitors
First Wave BioPharma Inc, Ratios based on current share price
First Wave BioPharma Inc, Annual Ratios
First Wave BioPharma Inc, Annual Ratios (Cont...1)
First Wave BioPharma Inc, Interim Ratios
First Wave BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
First Wave BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
First Wave BioPharma Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

First Wave BioPharma Inc, Performance Chart (2016 - 2020)

First Wave BioPharma Inc, Ratio Charts

First Wave BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

First Wave BioPharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

I would like to order

Product name: First Wave BioPharma Inc (FWBI) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/ACF0E1D9746EN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/ACF0E1D9746EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970